MIMEDX GROUP, INC. Form 10-Q May 01, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2015

OR

... TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______to____

Commission file number 001-35887

MIMEDX GROUP, INC.

(Exact name of registrant as specified in its charter)

Florida 26-2792552

(State or other jurisdiction of incorporation) (I.R.S. Employer Identification Number)

1775 West Oak Commons Ct NE 30062

Marietta, GA

(Address of principal executive offices) (Zip Code)

(770) 651-9100

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Non-accelerated filer "

Large accelerated filer " Accelerated filer x (Do not check if a smaller Smaller reporting company "

reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes "No x

As of April 15, 2015, there were 108,630,057 shares of the registrant's common stock outstanding.

Table of Contents

Part I	FINANCIAL INFORMATION	
Item 1	Condensed Consolidated Financial Statements	
	Condensed Consolidated Balance Sheets (unaudited) March 31, 2015 and December 31, 2014	· <u>4</u>
	Condensed Consolidated Statements of Operations (unaudited) Three Months Ended March	<u>5</u>
	31, 2015 and 2014	_
	Condensed Consolidated Statements of Stockholders' Equity (unaudited) for Three Months	<u>6</u>
	Ended March 31, 2015	_
	Condensed Consolidated Statements of Cash Flows (unaudited) Three Months Ended March 31, 2015 and 2014	7
	Notes to the Unaudited Condensed Consolidated Financial Statements Three Months Ended	8
	March 31, 2015 and 2014	
Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u> 19</u>
Item 3	Quantitative and Qualitative Disclosures About Market Risk	<u>23</u>
Item 4	Controls and Procedures	<u>24</u>
Part II (OTHER INFORMATION	
Item 1	Legal Proceedings	<u>24</u>
Item 1A	Risk Factors	<u>25</u>
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	<u>25</u>
Item 3	Defaults upon Senior Securities	<u> 26</u>
Item 4	Mine Safety Disclosures	<u> 26</u>
Item 5	Other Information	<u> 26</u>
Item 6	Exhibits	<u>27</u>
Signatur	es	<u>28</u>
2		

Forward-Looking Statements

This Form 10-Q and certain information incorporated herein by reference contain forward-looking statements and information within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of our products by the market, and management's plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission ("SEC"), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as "may," "could," "should," "would," "believe," "expect," "expectation," "anticipate," "estimate," "intend," "seeks," "plan," "project," "will," "should," and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference. These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.

Our actual results may differ materially from those expressed or implied in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those discussed in Part II, Item 1A, "Risk Factors," below and in our most recent Annual Report on Form 10-K, as well as other reports we file with the SEC. Except as expressly required by the federal securities laws, we undertake no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.

As used herein, the terms "MiMedx," "the Company," "we," "our" and "us" refer to MiMedx Group, Inc., a Florida corporatio and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.

3

Part I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

ASSETS Current assets: Cash and cash equivalents \$38,696 \$46,582 Short term investments 6,000 5,750 Accounts receivable, net 31,001 26,672 Inventory, net 4,248 5,133 Prepaid expenses and other current assets 2,341 1,540 Total current assets 82,286 85,677 Investments 2,500 3,250 Property and equipment, net of accumulated depreciation 6,440 5,447 Goodwill 4,040 4,040 Intangible assets, net of accumulated amortization 10,813 10,845
Cash and cash equivalents \$38,696 \$46,582 Short term investments 6,000 5,750 Accounts receivable, net 31,001 26,672 Inventory, net 4,248 5,133 Prepaid expenses and other current assets 2,341 1,540 Total current assets 82,286 85,677 Investments 2,500 3,250 Property and equipment, net of accumulated depreciation 6,440 5,447 Goodwill 4,040 4,040 Intangible assets, net of accumulated amortization 10,813 10,845
Short term investments 6,000 5,750 Accounts receivable, net 31,001 26,672 Inventory, net 4,248 5,133 Prepaid expenses and other current assets 2,341 1,540 Total current assets 82,286 85,677 Investments 2,500 3,250 Property and equipment, net of accumulated depreciation 6,440 5,447 Goodwill 4,040 4,040 Intangible assets, net of accumulated amortization 10,813 10,845
Accounts receivable, net 31,001 26,672 Inventory, net 4,248 5,133 Prepaid expenses and other current assets 2,341 1,540 Total current assets 82,286 85,677 Investments 2,500 3,250 Property and equipment, net of accumulated depreciation 6,440 5,447 Goodwill 4,040 4,040 Intangible assets, net of accumulated amortization 10,813 10,845
Inventory, net 4,248 5,133 Prepaid expenses and other current assets 2,341 1,540 Total current assets 82,286 85,677 Investments 2,500 3,250 Property and equipment, net of accumulated depreciation 6,440 5,447 Goodwill 4,040 4,040 Intangible assets, net of accumulated amortization 10,813 10,845
Prepaid expenses and other current assets2,3411,540Total current assets82,28685,677Investments2,5003,250Property and equipment, net of accumulated depreciation6,4405,447Goodwill4,0404,040Intangible assets, net of accumulated amortization10,81310,845
Total current assets82,28685,677Investments2,5003,250Property and equipment, net of accumulated depreciation6,4405,447Goodwill4,0404,040Intangible assets, net of accumulated amortization10,81310,845
Investments2,5003,250Property and equipment, net of accumulated depreciation6,4405,447Goodwill4,0404,040Intangible assets, net of accumulated amortization10,81310,845
Property and equipment, net of accumulated depreciation 6,440 5,447 Goodwill 4,040 4,040 Intangible assets, net of accumulated amortization 10,813 10,845
Goodwill 4,040 4,040 Intangible assets, net of accumulated amortization 10,813 10,845
Intangible assets, net of accumulated amortization 10,813 10,845
Other assets 26 —
Total assets \$106,105 \$109,259
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable \$5,379 \$3,661
Accrued compensation 8,720 11,523
Accrued expenses 3,615 2,504
Other current liabilities 746 716
Total current liabilities 18,460 18,404
Other liabilities 1,244 1,526
Total liabilities 19,704 19,930
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock; \$.001 par value; 5,000,000 shares authorized and 0 shares issued and
outstanding
Common stock; \$.001 par value; 130,000,000 shares authorized;
109,468,759 issued and 108,491,478 outstanding at March 31, 2015 109 108
and 108,776,247 issued and 107,789,611 outstanding at December 31, 2014
Additional paid-in capital 158,401 162,433
Treasury stock at cost:
977,281 shares at March 31, 2015 and 986,636 shares at December 31, 2014 (8,621) (5,637)
Accumulated deficit (63,488) (67,575)
Total stockholders' equity 86,401 89,329
Total liabilities and stockholders' equity \$106,105 \$109,259
See notes to condensed consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands except, share and per share data)

(unaudited)	

	Three Months 2015	Ended March 31, 2014	
	2013	2014	
Net sales	\$40,767	\$19,559	
Cost of sales	5,148	2,977	
Gross margin	35,619	16,582	
Operating expenses:			
Research and development expenses	1,831	1,390	
Selling, general and administrative expenses	29,308	15,852	
Amortization of intangible assets	233	231	
Operating income (loss)	4,247	(891)	
Other income (expense), net			
Interest expense, net	(14)	(21)	
Income (loss) before income tax provision	4,233	(912)	
Income tax provision	(146)	(10)	
Net Income (loss)	\$4,087	\$(922)	
Net income (loss) per common share - basic	\$0.04	\$(0.01)	
Net income (loss) per common share - diluted	\$0.04	\$(0.01)	
Weighted average shares outstanding - basic	ed average shares outstanding - basic 105,820,335		
Weighted average shares outstanding - diluted See notes to condensed consolidated financial statements	113,638,551	105,358,694	
5			

MIMEDX GROUP, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (in thousands, except share data) (unaudited)

	Common Stock Issued		Additional Paid-in	Treasury St		
	Shares	Amount	Capital	Shares	Amount	Accumulated Total Deficit
Balance December 31, 2014	108,776,247	\$108	\$162,433			